Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Narcotic Antagonists"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 711
Tytuł:
Healthcare provider perspectives on emergency department-initiated buprenorphine/naloxone: a qualitative study.
Autorzy:
Badke K; Lower Mainland Pharmacy Services, Vancouver, BC, Canada. .; Pharmacy Department, Vancouver General Hospital, 899 W 12th avenue, Vancouver, BC, V5Z 1M9, Canada. .; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada. .
Small SS; Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada.; Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada.
Pratt M; Social Work Department, Vancouver General Hospital, Vancouver, BC, Canada.
Lockington J; Department of Emergency Medicine, Vancouver General Hospital, Vancouver, BC, Canada.
Gurney L; Department of Emergency Medicine, Vancouver General Hospital, Vancouver, BC, Canada.; School of Nursing, University of British Columbia, Vancouver, BC, Canada.
Kestler A; Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada.; Department of Emergency Medicine, Vancouver General Hospital, Vancouver, BC, Canada.; Department of Emergency Medicine, St. Paul's Hospital, Vancouver, BC, Canada.
Moe J; Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada.; Department of Emergency Medicine, Vancouver General Hospital, Vancouver, BC, Canada.; Department of Emergency Medicine, BC Children's Hospital, Vancouver, BC, Canada.; BC Centre for Disease Control, Vancouver, BC, Canada.
Pokaż więcej
Źródło:
BMC health services research [BMC Health Serv Res] 2024 Feb 15; Vol. 24 (1), pp. 211. Date of Electronic Publication: 2024 Feb 15.
Typ publikacji:
Journal Article
MeSH Terms:
Opioid-Related Disorders*/epidemiology
Buprenorphine*/therapeutic use
Humans ; Narcotic Antagonists/therapeutic use ; Emergency Service, Hospital ; Health Personnel ; Naloxone/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Factors associated with frequent buprenorphine / naloxone initiation in a national survey of Canadian emergency physicians.
Autorzy:
MacKinnon N; Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada.; Department of Emergency Medicine, St. Paul's Hospital, Vancouver, British Columbia, Canada.
Lane D; Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada.
Scheuermeyer F; Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada.; Department of Emergency Medicine, St. Paul's Hospital, Vancouver, British Columbia, Canada.; Center for Health Evaluation and Outcome Sciences, Vancouver, British Columbia, Canada.
Kaczorowski J; Université de Montréal, Montreal, Quebec, Canada.
Dong K; Department of Emergency Medicine, University of Alberta, Edmonton, Alberta, Canada.
Orkin AM; Department of Family & Community Medicine, University of Toronto, Toronto, Ontario, Canada.
Daoust R; Université de Montréal, Montreal, Quebec, Canada.; Centre de Recherche de l'Hôpital Sacré-Coeur de Montréal, Montreal, Quebec, Canada.
Moe J; Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada.; British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada.
Andolfatto G; Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada.
Klaiman M; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Yan J; Division of Emergency Medicine, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
Koh JJ; Department of Emergency Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Crowder K; Department of Emergency Medicine, University of Calgary, Calgary, Alberta, Canada.
Atkinson P; Department of Emergency Medicine, Dalhousie University, St. John, New Brunswick, Canada.
Savage D; Division of Clinical Sciences, Northern Ontario School of Medicine, Thunder Bay, Ontario, Canada.
Stempien J; Department of Emergency Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Besserer F; Department of Emergency Medicine, University of British Columbia, Prince George, British Columbia, Canada.
Wale J; Department of Emergency Medicine, University of British Columbia, Victoria, British Columbia, Canada.
Kestler A; Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada.; Department of Emergency Medicine, St. Paul's Hospital, Vancouver, British Columbia, Canada.; Center for Health Evaluation and Outcome Sciences, Vancouver, British Columbia, Canada.; British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Feb 05; Vol. 19 (2), pp. e0297084. Date of Electronic Publication: 2024 Feb 05 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Buprenorphine*/therapeutic use
Opioid-Related Disorders*/drug therapy
Opioid-Related Disorders*/epidemiology
Opioid-Related Disorders*/complications
Humans ; Narcotic Antagonists/therapeutic use ; Canada/epidemiology ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Emergency Service, Hospital ; Cognition ; Naloxone/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder.
Autorzy:
Greenwald MK; Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI, USA. .
Wiest KL; Boulder Care, Portland, OR, USA.
Haight BR; Indivior, Inc., North Chesterfield, VA, USA.
Laffont CM; Indivior, Inc., North Chesterfield, VA, USA.
Zhao Y; Indivior, Inc., North Chesterfield, VA, USA.
Pokaż więcej
Źródło:
Harm reduction journal [Harm Reduct J] 2023 Dec 02; Vol. 20 (1), pp. 173. Date of Electronic Publication: 2023 Dec 02.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Buprenorphine*/therapeutic use
Opioid-Related Disorders*/drug therapy
Opioid-Related Disorders*/epidemiology
Adult ; Humans ; Analgesics, Opioid/therapeutic use ; Narcotic Antagonists/therapeutic use ; Treatment Outcome ; Delayed-Action Preparations/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A Guide to Expanding the Use of Buprenorphine Beyond Standard Initiations for Opioid Use Disorder.
Autorzy:
Miller JC; Psychiatry Residency Spokane, Providence Sacred Heart Medical Center and Children's Hospital, 101 W Eighth Ave, Spokane, WA, 99204, USA.
Brooks MA; Psychiatry Residency Spokane, Providence Sacred Heart Medical Center and Children's Hospital, 101 W Eighth Ave, Spokane, WA, 99204, USA.
Wurzel KE; Psychiatry Residency Spokane, Providence Sacred Heart Medical Center and Children's Hospital, 101 W Eighth Ave, Spokane, WA, 99204, USA.
Cox EJ; Providence Research Network, Renton, WA, USA.
Wurzel JF 3rd; Psychiatry Residency Spokane, Providence Sacred Heart Medical Center and Children's Hospital, 101 W Eighth Ave, Spokane, WA, 99204, USA. .
Pokaż więcej
Źródło:
Drugs in R&D [Drugs R D] 2023 Dec; Vol. 23 (4), pp. 339-362. Date of Electronic Publication: 2023 Nov 08.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Buprenorphine*/therapeutic use
Opioid-Related Disorders*/drug therapy
Pregnancy ; Female ; Adolescent ; Child ; Humans ; Narcotic Antagonists/therapeutic use ; Opiate Substitution Treatment/methods ; Analgesics, Opioid/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Impact of Emergency Department-Initiated Buprenorphine on Repeat Emergency Department Utilization.
Autorzy:
Skains RM; University of Alabama at Birmingham, Heersink School of Medicine, Department of Emergency Medicine, Birmingham, Alabama.; Birmingham VA Medical Center, Department of Emergency Medicine, Birmingham, Alabama.
Reynolds L; University of Alabama at Birmingham, Heersink School of Medicine, Department of Emergency Medicine, Birmingham, Alabama.
Carlisle N; University of Alabama at Birmingham, School of Public Health, Department of Health Behavior, Birmingham, Alabama.
Heath S; University of Alabama at Birmingham, Heersink School of Medicine, Department of Internal Medicine, Birmingham, Alabama.
Covington W; University of Alabama at Birmingham, Heersink School of Medicine, Department of Emergency Medicine, Birmingham, Alabama.
Hornbuckle K; University of Alabama at Birmingham, Heersink School of Medicine, Birmingham, Alabama.
Walter L; University of Alabama at Birmingham, Heersink School of Medicine, Department of Emergency Medicine, Birmingham, Alabama.
Pokaż więcej
Źródło:
The western journal of emergency medicine [West J Emerg Med] 2023 Nov; Vol. 24 (6), pp. 1010-1017.
Typ publikacji:
Journal Article
MeSH Terms:
Buprenorphine*/therapeutic use
Opioid-Related Disorders*/drug therapy
Opioid-Related Disorders*/epidemiology
Substance Withdrawal Syndrome*/drug therapy
Humans ; Male ; Female ; Narcotic Antagonists/therapeutic use ; Analgesics, Opioid/therapeutic use ; Retrospective Studies ; Opiate Substitution Treatment ; Naloxone/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Disparities in Emergency Department Naloxone and Buprenorphine Initiation.
Autorzy:
Papp J; MetroHealth Campus of Case Western Reserve University, Department of Emergency Medicine, Cleveland, Ohio.
Emerman C; MetroHealth Campus of Case Western Reserve University, Department of Emergency Medicine, Cleveland, Ohio.
Pokaż więcej
Źródło:
The western journal of emergency medicine [West J Emerg Med] 2023 Jun 30; Vol. 24 (4), pp. 710-716. Date of Electronic Publication: 2023 Jun 30.
Typ publikacji:
Journal Article
MeSH Terms:
Buprenorphine*/therapeutic use
Opioid-Related Disorders*/drug therapy
Drug Overdose*/drug therapy
Humans ; Female ; Male ; Naloxone/therapeutic use ; Analgesics, Opioid/therapeutic use ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Emergency Service, Hospital ; Narcotic Antagonists/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Use of a sequential multiple assignment randomized trial to test contingency management and an integrated behavioral economic and mindfulness intervention for buprenorphine-naloxone medication adherence for opioid use disorder.
Autorzy:
Peter SC; Department of Psychology, Durham VA Medical Center, 508 Fulton Street, Durham, NC, 27705, USA.
Murphy JG; Department of Psychology, The University of Memphis, 400 Innovation Drive, Memphis, TN, 38152-6400, USA.
Witkiewitz K; Department of Psychology, University of New Mexico, Logan Hall, Albuquerque, NM, 87131-0001, USA.
Hand SB; Department of Preventive Medicine, University of Tennessee Health Science Center, 66 N Pauline St, Memphis, TN, 38163, USA.
Thomas F; Department of Preventive Medicine, University of Tennessee Health Science Center, 66 N Pauline St, Memphis, TN, 38163, USA.
Johnson KC; Department of Preventive Medicine, University of Tennessee Health Science Center, 66 N Pauline St, Memphis, TN, 38163, USA.
Cowan R; Department of Psychiatry, University of Tennessee Health Science Center, 920 Madison Avenue, Memphis, TN, 38163, USA.
Harris M; Boyd Center for Business and Economic Research, University of Tennessee, 1000 Volunteer Boulevard, Knoxville, TN, 37996, USA.
Derefinko KJ; Department of Preventive Medicine, University of Tennessee Health Science Center, 66 N Pauline St, Memphis, TN, 38163, USA. .
Pokaż więcej
Źródło:
Trials [Trials] 2023 Mar 29; Vol. 24 (1), pp. 237. Date of Electronic Publication: 2023 Mar 29.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Mindfulness*
Opioid-Related Disorders*/diagnosis
Opioid-Related Disorders*/drug therapy
Opioid-Related Disorders*/psychology
Buprenorphine*/therapeutic use
Adult ; Humans ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Narcotic Antagonists/adverse effects ; Economics, Behavioral ; Medication Adherence ; Opiate Substitution Treatment/methods
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The Impact of a Peer-Navigator Program on Naloxone Distribution and Buprenorphine Utilization in the Emergency Department.
Autorzy:
Ramdin C; Department of Emergency Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Guo M; Department of Emergency Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Fabricant S; Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
Santos C; Department of Emergency Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Nelson L; Department of Emergency Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Pokaż więcej
Źródło:
Substance use & misuse [Subst Use Misuse] 2022; Vol. 57 (4), pp. 581-587. Date of Electronic Publication: 2021 Dec 31.
Typ publikacji:
Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:
Buprenorphine*/therapeutic use
Emergency Service, Hospital*
Naloxone*/therapeutic use
Narcotic Antagonists*/therapeutic use
Opioid-Related Disorders*/drug therapy
Buprenorphine, Naloxone Drug Combination/therapeutic use ; COVID-19 ; Humans ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection.
Autorzy:
Hassman H; Hassman Research Institute, Marlton, NJ, USA.
Strafford S; Indivior Inc, Richmond, VA, USA.
Shinde SN; Indivior Inc, Richmond, VA, USA.
Heath A; Indivior Inc, Richmond, VA, USA.
Boyett B; Bradford Health Services, Birmingham, AL, USA.
Dobbins RL; Indivior Inc, Richmond, VA, USA.
Pokaż więcej
Źródło:
The American journal of drug and alcohol abuse [Am J Drug Alcohol Abuse] 2023 Jan 02; Vol. 49 (1), pp. 43-52. Date of Electronic Publication: 2022 Aug 24.
Typ publikacji:
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Buprenorphine*/therapeutic use
Opioid-Related Disorders*/drug therapy
Substance Withdrawal Syndrome*/drug therapy
Humans ; Male ; Analgesics, Opioid/therapeutic use ; Delayed-Action Preparations/therapeutic use ; Injections, Subcutaneous ; Naltrexone/therapeutic use ; Narcotic Antagonists/therapeutic use ; Pilot Projects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Developing A Rapid Transfer from Opioid Full Agonist to Buprenorphine: "Ultrarapid Micro-Dosing" Proof of Concept.
Autorzy:
Azar P; Complex Pain and Addiction Services, Vancouver General Hospital, Vancouver, BC, Canada.; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
Mathew N; Complex Pain and Addiction Services, Vancouver General Hospital, Vancouver, BC, Canada.; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.; Department of the Provincial Health Services Authority, BC Mental Health & Substance Use Services, Provincial Health Services Authority, BC, Canada.
Mahal D; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
Wong JSH; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
Westenberg JN; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
Schütz CG; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.; Department of the Provincial Health Services Authority, BC Mental Health & Substance Use Services, Provincial Health Services Authority, BC, Canada.
Greenwald MK; Department of Psychiatry and Behavioral Neurosciences, School of Medicine, and Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA.
Pokaż więcej
Źródło:
Journal of psychoactive drugs [J Psychoactive Drugs] 2023 Jan-Mar; Vol. 55 (1), pp. 94-101. Date of Electronic Publication: 2022 Feb 13.
Typ publikacji:
Journal Article
MeSH Terms:
Buprenorphine*
Opioid-Related Disorders*/drug therapy
Humans ; Analgesics, Opioid/therapeutic use ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Opiate Substitution Treatment/methods ; Narcotic Antagonists/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Treatment Experiences for Patients Receiving Buprenorphine/Naloxone for Opioid Use Disorder: A Qualitative Study of Patients' Perceptions and Attitudes.
Autorzy:
Young GJ; Center for Health Policy and Healthcare Research, Northeastern University, Boston, Massachusetts, USA.; Bouve College of Health Sciences, Northeastern University, Boston, Massachusetts, USA.; D'Amore-Mckim School of Business, Northeastern University, Boston, Massachusetts, USA.
Hasan MM; Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.; Department of Information Systems and Operations Management, College of Business, University of Florida, Gainesville, USA.; Center for Drug Evaluation and Safety, University of Florida, Gainesville, Florida, USA.
Young LD; Prescription Monitoring Program, Massachusetts Department of Public Health, Boston, Massachusetts, USA.
Noor-E-Alam M; Center for Health Policy and Healthcare Research, Northeastern University, Boston, Massachusetts, USA.; Department of Mechanical and Industrial Engineering, Northeastern University, Boston, Massachusetts, USA.
Pokaż więcej
Źródło:
Substance use & misuse [Subst Use Misuse] 2023; Vol. 58 (4), pp. 512-519. Date of Electronic Publication: 2023 Feb 10.
Typ publikacji:
Journal Article; Research Support, U.S. Gov't, P.H.S.
MeSH Terms:
Buprenorphine*/therapeutic use
Opioid-Related Disorders*/drug therapy
Opioid-Related Disorders*/rehabilitation
Male ; Humans ; Female ; Adult ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Analgesics, Opioid/therapeutic use ; Attitude ; Opiate Substitution Treatment/methods ; Narcotic Antagonists/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effectiveness of two extended-release buprenorphine formulations during postoperative period in neonatal rats.
Autorzy:
Zhang M; Department of Comparative Medicine, Stanford University School of Medicine, Stanford, California, United States of America.
Alamaw E; Department of Comparative Medicine, Stanford University School of Medicine, Stanford, California, United States of America.
Jampachaisri K; Department of Mathematics, Naresuan University, Phitsanulok, Thailand.
Huss M; Department of Comparative Medicine, Stanford University School of Medicine, Stanford, California, United States of America.
Pacharinsak C; Department of Comparative Medicine, Stanford University School of Medicine, Stanford, California, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2022 Oct 17; Vol. 17 (10), pp. e0276327. Date of Electronic Publication: 2022 Oct 17 (Print Publication: 2022).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Buprenorphine*/therapeutic use
Opioid-Related Disorders*/drug therapy
Tissue Adhesives*/therapeutic use
Analgesics, Opioid/therapeutic use ; Animals ; Animals, Newborn ; Delayed-Action Preparations/therapeutic use ; Female ; Humans ; Male ; Narcotic Antagonists/therapeutic use ; Postoperative Period ; Rats ; Sevoflurane/therapeutic use ; Sodium Chloride/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Lower buprenorphine elimination rate constant is associated with lower opioid use.
Autorzy:
Elarabi HF; National Rehabilitation Centre, Abu Dhabi, United Arab Emirates. .; Addictions Department, Division of Academic Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. .
Lee AJ; Medical Statistics Team, University of Aberdeen, Aberdeen, UK.
Adem A; Faculty of Medicine, Khalifa University, Abu Dhabi, United Arab Emirates.
Elrasheed A; National Rehabilitation Centre, Abu Dhabi, United Arab Emirates.
Marsden J; Addictions Department, Division of Academic Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Al Ghaferi H; International Society of Addiction Medicine, Abu Dhabi, United Arab Emirates.
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2022 Oct; Vol. 239 (10), pp. 3213-3221. Date of Electronic Publication: 2022 Aug 12.
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Buprenorphine*/therapeutic use
Opioid-Related Disorders*/drug therapy
Adult ; Analgesics, Opioid/therapeutic use ; Humans ; Narcotic Antagonists/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Modeling the cost-effectiveness and impact on fatal overdose and initiation of buprenorphine-naloxone treatment at syringe service programs.
Autorzy:
Adams JW; Section of Infectious Diseases, Boston Medical Center (BMC), Boston, MA, USA.; RTI International, Research Triangle, NC, USA.
Savinkina A; Section of Infectious Diseases, Boston Medical Center (BMC), Boston, MA, USA.
Fox A; Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY, USA.
Behrends CN; Department of Population Health Sciences, Weill Cornell Medical College, New York City, NY, USA.
Madushani RWMA; Section of Infectious Diseases, Boston Medical Center (BMC), Boston, MA, USA.
Wang J; Section of Infectious Diseases, Boston Medical Center (BMC), Boston, MA, USA.
Chatterjee A; Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Boston Medical Center, Boston, MA, USA.; Boston University School of Medicine, Boston, MA, USA.
Walley AY; Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Boston Medical Center, Boston, MA, USA.; Boston University School of Medicine, Boston, MA, USA.
Barocas JA; Divisions of General Internal Medicine and Infectious Diseases, University of Colorado School of Medicine, Aurora, CO, USA.
Linas BP; Section of Infectious Diseases, Boston Medical Center (BMC), Boston, MA, USA.; Boston University School of Medicine, Boston, MA, USA.
Pokaż więcej
Źródło:
Addiction (Abingdon, England) [Addiction] 2022 Oct; Vol. 117 (10), pp. 2635-2648. Date of Electronic Publication: 2022 Apr 03.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Buprenorphine*/therapeutic use
Drug Overdose*/drug therapy
Opiate Overdose*
Opioid-Related Disorders*/epidemiology
Analgesics, Opioid/therapeutic use ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Cost-Benefit Analysis ; Humans ; Narcotic Antagonists ; Opiate Substitution Treatment/methods ; Syringes
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Kamini, a little recognised source of illicit opioid: A case series of 12 patients.
Autorzy:
Khan T; Addiction Service, Metro South Health, Logan, Australia.
Ariyawansa P; Alcohol and Other Drug Service, Gold Coast Health, Gold Coast, Australia.
Quinn J; Alcohol and Drug Service, West Moreton Health, Ipswich, Australia.
Hayllar J; Alcohol and Drug Service, Metro North Health, Brisbane, Australia.
Pokaż więcej
Źródło:
Drug and alcohol review [Drug Alcohol Rev] 2022 Sep; Vol. 41 (6), pp. 1404-1407. Date of Electronic Publication: 2022 May 12.
Typ publikacji:
Journal Article
MeSH Terms:
Buprenorphine*/therapeutic use
COVID-19*
Opioid-Related Disorders*/drug therapy
Opioid-Related Disorders*/rehabilitation
Analgesics, Opioid/therapeutic use ; Humans ; Methadone/therapeutic use ; Narcotic Antagonists/therapeutic use ; Opiate Substitution Treatment ; Pandemics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.
Autorzy:
Marsden J; Addictions Department, Institute of Psychiatry, Psychology & Neuroscience, Division of Academic Psychiatry, King's College London, Addiction Sciences Building, 4 Windsor Walk, Denmark Hill, London, SE5 8AF, UK. .; South London & Maudsley NHS Foundation Trust, London, UK. .
Kelleher M; South London & Maudsley NHS Foundation Trust, London, UK.
Hoare Z; School of Health Sciences, Bangor University, Bangor, Wales, UK.
Hughes D; Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, Wales, UK.
Bisla J; King's Clinical Trials Unit, Research Management and Innovation Directorate, King's College London, London, UK.
Cape A; King's Clinical Trials Unit, Research Management and Innovation Directorate, King's College London, London, UK.
Cowden F; NHS Tayside, Dundee, Scotland, UK.
Day E; Birmingham & Solihull Mental Health, NHS Foundation Trust, Birmingham, UK.
Dewhurst J; Addictions Division, Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK.
Evans R; School of Health Sciences, Bangor University, Bangor, Wales, UK.
Hearn A; Northumberland, Tyne & Wear NHS Foundation Trust, Newcastle Addictions Service, Newcastle Upon Tyne, UK.
Kelly J; King's Clinical Trials Unit, Research Management and Innovation Directorate, King's College London, London, UK.
Lowry N; Addictions Department, Institute of Psychiatry, Psychology & Neuroscience, Division of Academic Psychiatry, King's College London, Addiction Sciences Building, 4 Windsor Walk, Denmark Hill, London, SE5 8AF, UK.; South London & Maudsley NHS Foundation Trust, London, UK.
McCusker M; Patient and Public Involvement Representative, Lambeth Service User Council, South London & Maudsley NHS Foundation Trust, London, UK.
Murphy C; King's Clinical Trials Unit, Research Management and Innovation Directorate, King's College London, London, UK.
Murray R; Northumberland, Tyne & Wear NHS Foundation Trust, Newcastle Addictions Service, Newcastle Upon Tyne, UK.
Myton T; Addictions Division, Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK.
Quarshie S; Northumberland, Tyne & Wear NHS Foundation Trust, Newcastle Addictions Service, Newcastle Upon Tyne, UK.
Scott G; South London & Maudsley NHS Foundation Trust, London, UK.
Turner S; South London & Maudsley NHS Foundation Trust, London, UK.
Vanderwaal R; South London & Maudsley NHS Foundation Trust, London, UK.
Wareham A; Patient and Public Involvement Representative, London, UK.
Gilvarry E; Northumberland, Tyne & Wear NHS Foundation Trust, Newcastle Addictions Service, Newcastle Upon Tyne, UK.
Mitcheson L; Addictions Department, Institute of Psychiatry, Psychology & Neuroscience, Division of Academic Psychiatry, King's College London, Addiction Sciences Building, 4 Windsor Walk, Denmark Hill, London, SE5 8AF, UK.; South London & Maudsley NHS Foundation Trust, London, UK.
Pokaż więcej
Źródło:
Trials [Trials] 2022 Aug 19; Vol. 23 (1), pp. 697. Date of Electronic Publication: 2022 Aug 19.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Buprenorphine*/adverse effects
Methadone*/adverse effects
Opioid-Related Disorders*/drug therapy
Adult ; Analgesics, Opioid/adverse effects ; Cost-Benefit Analysis ; Delayed-Action Preparations/therapeutic use ; Humans ; Multicenter Studies as Topic ; Narcotic Antagonists/adverse effects ; Pragmatic Clinical Trials as Topic ; Randomized Controlled Trials as Topic ; State Medicine ; Tablets/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA.
Autorzy:
Hill LG; College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
Loera LJ; College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
Evoy KE; College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
Renfro ML; College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
Torrez SB; College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
Zagorski CM; College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
Perez JC; College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
Jones SM; Department of Psychiatry and Behavioral Sciences, University of Texas Health San Antonio, Austin, TX, USA.
Reveles KR; College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
Pokaż więcej
Źródło:
Addiction (Abingdon, England) [Addiction] 2021 Jun; Vol. 116 (6), pp. 1505-1511. Date of Electronic Publication: 2020 Nov 22.
Typ publikacji:
Journal Article
MeSH Terms:
Buprenorphine*
Naloxone*/therapeutic use
Narcotic Antagonists*/therapeutic use
Pharmacies*
Cross-Sectional Studies ; Health Services Accessibility ; Humans ; Nasal Sprays ; Texas
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Pharmacokinetics of buprenorphine in pregnant sheep after intravenous injection.
Autorzy:
Hakomäki H; School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
Kokki H; School of Medicine, University of Eastern Finland, Kuopio, Finland.
Lehtonen M; School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
Ranta VP; School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
Räsänen J; Department of Obstetrics and Gynecology, Helsinki University Hospital, Helsinki, Finland.
Voipio HM; Department of Experimental Surgery, Oulu Laboratory Animal Centre, Oulu University Hospital and University of Oulu, Oulu, Finland.
Kokki M; Department of Anesthesia and Intensive Care, Kuopio University Hospital, Kuopio, Finland.
Pokaż więcej
Źródło:
Pharmacology research & perspectives [Pharmacol Res Perspect] 2021 Apr; Vol. 9 (2), pp. e00726.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms:
Buprenorphine/*pharmacokinetics
Narcotic Antagonists/*pharmacokinetics
Opiate Substitution Treatment/*methods
Opioid-Related Disorders/*rehabilitation
Pregnancy Complications/*rehabilitation
Animals ; Buprenorphine/administration & dosage ; Disease Models, Animal ; Female ; Humans ; Injections, Intravenous ; Metabolic Clearance Rate ; Narcotic Antagonists/administration & dosage ; Opioid-Related Disorders/blood ; Pregnancy ; Pregnancy Complications/blood ; Sheep
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Improving Uptake of Emergency Department-initiated Buprenorphine: Barriers and Solutions.
Autorzy:
Kelly TD; Indiana University Emergency Medicine Residency, Indianapolis, Indiana.
Hawk KF; Yale School of Medicine, Department of Emergency Medicine, New Haven, Connecticut.
Samuels EA; Alpert Medical School of Brown University, Department of Emergency Medicine, Providence, Rhode Island.
Strayer RJ; Maimonides Medical Center, Department of Emergency Medicine, Brooklyn, New York.
Hoppe JA; University of Colorado School of Medicine, Department of Emergency Medicine, Aurora, Colorado.
Pokaż więcej
Źródło:
The western journal of emergency medicine [West J Emerg Med] 2022 Jul 11; Vol. 23 (4), pp. 461-467. Date of Electronic Publication: 2022 Jul 11.
Typ publikacji:
Journal Article
MeSH Terms:
Buprenorphine*/therapeutic use
Emergency Medicine*
Opioid-Related Disorders*/drug therapy
Emergency Service, Hospital ; Humans ; Narcotic Antagonists/therapeutic use ; Opiate Substitution Treatment
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Long-term patient outcomes following buprenorphine/naloxone treatment for opioid use disorder: a retrospective analysis in a commercially insured population.
Autorzy:
Hasan MM; Department of Mechanical and Industrial Engineering, College of Engineering, Center for Health Policy and Healthcare Research, Northeastern University, Boston, MA, USA.
Noor-E-Alam M; Department of Mechanical and Industrial Engineering, College of Engineering, Center for Health Policy and Healthcare Research, Northeastern University, Boston, MA, USA.
Shi J; Department of Mechanical and Industrial Engineering, College of Engineering, Northeastern University, Boston, MA, USA.
Young LD; Massachusetts Department of Public Health, Prescription Monitoring Program, Boston, MA, USA.
Young GJ; School of Business, Bouve College of Health Sciences, Center for Health Policy and Healthcare Research, Northeastern UniversityD'Amore-McKim, Boston, MA, USA.
Pokaż więcej
Źródło:
The American journal of drug and alcohol abuse [Am J Drug Alcohol Abuse] 2022 Jul 04; Vol. 48 (4), pp. 481-491. Date of Electronic Publication: 2022 Jun 07.
Typ publikacji:
Journal Article; Research Support, U.S. Gov't, P.H.S.
MeSH Terms:
Buprenorphine*/therapeutic use
Opioid-Related Disorders*/drug therapy
Opioid-Related Disorders*/epidemiology
Analgesics, Opioid/therapeutic use ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Female ; Humans ; Longitudinal Studies ; Male ; Narcotic Antagonists/therapeutic use ; Opiate Substitution Treatment/methods ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 711

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies